

Date: October 26, 2020

To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Company Code No. AUROPHARMA	To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804
--	--

Dear Sir,

Sub: Disposal of business assets of Natrol LLC, a wholly owned step-down subsidiary in USA.


In accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirement) Regulation, 2015, we hereby inform you that Natrol LLC, USA, a wholly owned step-down subsidiary of the Company, has entered into a definite agreement with New Mountain Capital LLC, NY and its affiliate Jarrow Formulas Inc., to dispose of its business assets as a going concern with related assets, liabilities, products, brands and employees.

The disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Part A of Schedule III of the aforesaid regulations, is enclosed as '**Annexure I**'.

Also attached a copy of press release as '**Annexure II**'.

We request you to take the same on record.

Yours faithfully,
For AUROBINDO PHARMA LIMITED



B. Adi Reddy
Company Secretary

Encl: Annexures I & II

AUROBINDO PHARMA LIMITED

(CIN :L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp off.: The Water Mark Building, Plot No.11, Survey No.9, Hi-tech City, Kondapur, Hyderabad – 500 084 T.S., INDIA Tel : +91 40 6672 5000 | 1200 Fax : +91 40 6707 4059
Regd. Off. : Plot No. 2, Maitrivihar, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel : +91 40 2373 6370 Fax : +91 40 2374 7340, Email : info@aurobindo.com

www.aurobindo.com

Annexure - I

Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

a	Name of the subsidiary whose business assets are to be disposed of	Natrol LLC., a wholly owned subsidiary of Aurobindo Pharma USA Inc., USA which in turn is a wholly owned subsidiary of the Company.
b	The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division during the last financial year	Turnover for the financial year ended 31.03.2020 is USD 156.66 million The net worth as on 31.03.2020 is USD 82.41 million
c	Date on which the agreement for sale has been entered into	25 th October 2020
d	The expected date of completion of Sale/disposal	The transaction is expected to close by January 2021
e	Consideration received from such sale/disposal	Cash of USD 550 million to be received from the disposal.
f	Brief details of buyers and whether any of the buyers belong to the promoter/ promoter group companies. If yes, details thereof	New Mountain Capital LLC, NY and its affiliate Jarrow Formulas Inc are the buyers. The buyer does not belong to the promoter/promoter group companies.
g	Whether the transaction would fall within related party transactions? If yes, whether the same is done at 'arm's length'	The transaction is not a related party transaction
h	Additionally in case of slump sale, indicative disclosures provided for amalgamation/ merger, shall be disclosed by the listed entity with respect to slump sale.	Not applicable.

AUROBINDO PHARMA LIMITED

(CIN :L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp off.: The Water Mark Building, Plot No.11, Survey No.9, Hi-tech City, Kondapur, Hyderabad – 500 084 T.S., INDIA Tel : +91 40 6672 5000 | 1200 Fax : +91 40 6707 4059
Regd. Off. : Plot No. 2, Maitrivihar, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel : +91 40 2373 6370 Fax : +91 40 2374 7340, Email : info@aurobindo.com

www.aurobindo.com

Annexure - II
(Press Release)

NEWS RELEASE

26 Oct 2020, Hyderabad, India

Aurobindo Pharma to divest Natrol to New Mountain Capital

Aurobindo Pharma is pleased to announce that the Company has reached a definitive agreement to sell Natrol LLC., a wholly owned subsidiary of Aurobindo Pharma USA, Inc., to an affiliate of New Mountain Capital to combine with Jarrow Formulas.

The all-cash transaction is valued at USD 550 Million (or INR 4,048 Cr at the current exchange rate). Subject to customary closing conditions and regulatory approvals, the transaction is expected to close by January 2021.

Natrol's annual sales for the 12 months ended March 31, 2020 was about USD 157 Million.

Following the acquisition of the assets of Natrol by Aurobindo Pharma in December 2014, Natrol has been a consistently profitable business, growing on all fronts under Aurobindo's ownership.

"Aurobindo is committed to evaluating and concluding strategic options towards focused portfolio enhancement with the ultimate objective of enhancing stakeholder values. We are pleased to sell the Natrol business to an outstanding private equity player, who could focus additional resources to grow Natrol, its products and brands further."

"On behalf of Aurobindo Group, my heartfelt thanks to all stakeholders including employees, who have supported in acquiring and bringing Natrol to a growth path in the past 6 years," said Mr. N. Govindarajan, Managing Director, Aurobindo Pharma Limited. He also said "Proceeds from Natrol's divestiture will be used to reduce debt and other new strategic initiatives."

Jefferies served as the sole financial advisor to Aurobindo, and Sullivan & Cromwell LLP acted as legal counsel to Aurobindo

About Aurobindo Pharma Limited:

Aurobindo Pharma Limited (www.aurobindo.com) (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP:IN), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, Japan PMDA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 7 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, Anti-Allergies and Anti-Diabetics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 150 countries.

AUROBINDO PHARMA LIMITED

(CIN :L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp off.: The Water Mark Building, Plot No.11, Survey No.9, Hi-tech City, Kondapur, Hyderabad – 500 084 T.S., INDIA Tel : +91 40 6672 5000 | 1200 Fax : +91 40 6707 4059
Regd. Off. : Plot No. 2, Maitrivihar, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel : +91 40 2373 6370 Fax : +91 40 2374 7340, Email : info@aurobindo.com

www.aurobindo.com

For further information, please contact:

Krishna Kiran
Investor Relations
Phone: 040-66725401 / 66725000
Mobile: +91 98486 67906
Email: ir@aurobindo.com

Disclaimer:

This press release contain statements that may constitute “forward looking statements” including and without limitation, statements relating to product characteristics and uses, sales potential and target dates for product launch, implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. While these forward looking statements represent our judgment and future expectations concerning the development of our business, a number of risks, uncertainties and other factors could cause actual developments and results to differ materially from our expectations. The company undertakes no obligation to publicly revise any forward looking statements to reflect future events or circumstances and will not be held liable for any use of this information.

AUROBINDO PHARMA LIMITED

(CIN :L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp off.: The Water Mark Building, Plot No.11, Survey No.9, Hi-tech City, Kondapur, Hyderabad – 500 084 T.S., INDIA Tel : +91 40 6672 5000 | 1200 Fax : +91 40 6707 4059
Regd. Off. : Plot No. 2, Maitrivihar, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel : +91 40 2373 6370 Fax : +91 40 2374 7340, Email : info@aurobindo.com

www.aurobindo.com